Trade Entero Therapeutics Inc - ENTO CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0121 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.359 |
| Open | 0.3499 |
| 1-Year Change | -87.97% |
| Day's Range | 0.3297 - 0.359 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 0.3590 | -0.0197 | -5.20% | 0.3787 | 0.3789 | 0.3582 |
| Apr 23, 2025 | 0.3589 | 0.0100 | 2.87% | 0.3489 | 0.3754 | 0.3489 |
| Apr 22, 2025 | 0.3563 | 0.0274 | 8.33% | 0.3289 | 0.3678 | 0.3189 |
| Apr 21, 2025 | 0.3459 | -0.0130 | -3.62% | 0.3589 | 0.3589 | 0.3265 |
| Apr 17, 2025 | 0.3610 | -0.0179 | -4.72% | 0.3789 | 0.3839 | 0.3571 |
| Apr 16, 2025 | 0.3789 | 0.0000 | 0.00% | 0.3789 | 0.3840 | 0.3789 |
| Apr 15, 2025 | 0.3990 | 0.0101 | 2.60% | 0.3889 | 0.4037 | 0.3889 |
| Apr 14, 2025 | 0.3928 | 0.0139 | 3.67% | 0.3789 | 0.3977 | 0.3789 |
| Apr 11, 2025 | 0.3825 | -0.0103 | -2.62% | 0.3928 | 0.4109 | 0.3789 |
| Apr 10, 2025 | 0.4016 | 0.0088 | 2.24% | 0.3928 | 0.4189 | 0.3928 |
| Apr 9, 2025 | 0.4364 | 0.0475 | 12.21% | 0.3889 | 0.4649 | 0.3889 |
| Apr 8, 2025 | 0.4190 | -0.0129 | -2.99% | 0.4319 | 0.4489 | 0.3989 |
| Apr 7, 2025 | 0.4694 | 0.0485 | 11.52% | 0.4209 | 0.4889 | 0.4189 |
| Apr 4, 2025 | 0.4795 | -0.0464 | -8.82% | 0.5259 | 0.5413 | 0.3689 |
| Apr 3, 2025 | 0.4085 | -0.0005 | -0.12% | 0.4090 | 0.4227 | 0.3606 |
| Apr 2, 2025 | 0.4099 | -0.0332 | -7.49% | 0.4431 | 0.4431 | 0.4089 |
| Apr 1, 2025 | 0.3989 | -0.0800 | -16.70% | 0.4789 | 0.4789 | 0.3890 |
| Mar 31, 2025 | 0.4790 | 0.0090 | 1.91% | 0.4700 | 0.4984 | 0.4700 |
| Mar 28, 2025 | 0.4792 | -0.0397 | -7.65% | 0.5189 | 0.5189 | 0.4788 |
| Mar 27, 2025 | 0.5339 | -0.0111 | -2.04% | 0.5450 | 0.5589 | 0.5332 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
First Wave BioPharma, Inc. Company profile
About First Wave BioPharma Inc
First Wave BioPharma, Inc., formerly AzurRx BioPharma, Inc., is a clinical-stage biopharmaceutical company. It is engaged in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. It is focused on advancing a therapeutic development pipeline built around its two technologies: niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The Company's niclosamide portfolio is led by three clinical programs: FW-COV, for COVID-19 gastrointestinal infections; FW-UP, for ulcerative proctitis (UP) and ulcerative proctosigmoiditis; and FW-ICI-AC, for Grade 1 and Grade 2 immune checkpoint inhibitor-associated colitis and diarrhea in advanced oncology patients. It is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
Financial summary
BRIEF: For the nine months ended 30 September 2021, First Wave BioPharma Inc revenues was not reported. Net loss applicable to common stockholders increased from $23.4M to $73.2M. Higher net loss reflects Research and development expenses - Bala increase of 85% to $8.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$8.35 to -$10.31.
| Industry: | Biotechnology & Medical Research (NEC) |
777 Yamato Road
Suite 502
BOCA RATON
FLORIDA 33431
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com